Click here to go to the previous page
FDA Regulations for Cellular Therapy Products: What Applies Now
Program Code:
9109-QE-CT
Date:
Saturday, October 24, 2009
Time:
10:30 AM to 12:00 PM
EST
DIRECTOR
:
Janice Davis-Sproul, MAS, MT(ASCP)SBB, Manager, Cell Therapy Laboratory, Johns Hopkins Medicine
MODERATOR
:
Janice Davis-Sproul, MAS, MT(ASCP)SBB, Manager, Cell Therapy Laboratory, Johns Hopkins Medicine
SPEAKER
:
Ellen F. Lazarus, MD, CAPT, USPHS, Medical Officer, Food and Drug Adminstration
Description
The FDA uses a risk-based approach for the regulation of human cells and tissues. This means that the regulations can be applied to a wide variety of products and that the type of regulation is commensurate with the risk posed by the product. This approach has yielded two categories of cell and tissue-based products, often referred to as 351 and 361 products.
This session will use lectures and case studies to review and interpret FDA regulations for Cellular and Tissue-Based Products. The focus will be on understanding the framework of product classification in order to determine which products require an IND/IDE and which do not.
-
Apply the regulations to determine if a product is a '351' (GMP) product or a '361' (GTP) product.
-
Discuss the impact of 2008/2009 FDA Cellular Therapy Product guidances on the processing laboratory.
-
Review FDA regulations for biological products that contain cells and/or tissue.
CE Category | CE Value |
---|
California Clinical Laboratory Personnel |
1.5 |
California Nurse |
1.8 |
Florida Laboratory Personnel |
1.8 |
General Attendee |
1.5 |
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.